MTR-106 is a potent and orally active G-quadruplex stabilizer and RNA polymerase I inhibitor. MTR-106 induces apoptosis and inhibits cell growth. MTR-106 can be used in research of cancer.
MTR-106 (0-100 μM; 7 d) has antitumor activity in both HR-deficient cells and PARPi-resistant cells[1].MTR-106 (0-100 μM; 7 d) induces apoptosis, cell cycle arrest and DNA damage[1].
MTR-106 (10-30 mg/kg; p.o.; twice a week, for 29 days) suppresses the tumor growth of BRCA-deficient and PARPi-resistant xenografts in nude mice[1].
References:
[1]. Li MZ, et, al. Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancers. Invest New Drugs. 2021 Oct;39(5):1213-1221.